All Stories

  1. Severe Acute Respiratory Syndrome Coronavirus 2 and Blood Safety: An Updated Review
  2. Effect of HIV pre‐exposure prophylaxis (PrEP) on detection of early infection and its impact on the appropriate post‐PrEP deferral period
  3. Severe acute respiratory syndrome coronavirus‐2: implications for blood safety and sufficiency
  4. Modeling the West Nile virus transfusion transmission risk in a nonoutbreak country associated with traveling donors
  5. Attitudes and willingness to donate blood among gay and bisexual men in Australia
  6. Blood donation amongst people who inject drugs in Australia: research supporting policy change
  7. HIV residual risk in Canada under a three‐month deferral for men who have sex with men
  8. Confirming transfusion‐transmitted viral infections in the molecular age: time to get back to the basic definition of infection for hemovigilance
  9. Blood safety assessment of hepatitis A outbreak linked to frozen pomegranate arils: are foodborne outbreaks an emerging blood safety risk?
  10. Tattoos, blood‐borne viruses and blood donors: a blood donor cohort and risk assessment
  11. Changing the deferral for men who have sex with men – an improved model to estimate HIV residual risk
  12. Undetectable does not equal untransmittable for HIV and blood transfusion
  13. No evidence for widespread Babesia microti transmission in Australia
  14. International forum on Occult hepatitis B infection and transfusion safety
  15. Modelling the risk of transfusion-transmitted syphilis: a reconsideration of blood donation testing strategies
  16. Estimation of human T-lymphotropic virus incidence in blood donors from observed prevalence
  17. Creutzfeldt-Jakob disease and blood transfusion safety
  18. Emerging infectious disease outbreaks: estimating disease risk in Australian blood donors travelling overseas
  19. Reconsideration of blood donation testing strategy for human T-cell lymphotropic virus in Australia
  20. Value of retaining HBsAg donor screening where HBV NAT and anti-HBc donor screening apply
  21. Hepatitis E virus RNA in Australian blood donors: prevalence and risk assessment
  22. HIV pre-exposure prophylaxis (PrEP) and blood donation
  23. Hepatitis E virus seroepidemiology: a post-earthquake study among blood donors in Nepal
  24. Refining the risk estimate for transfusion-transmission of occult hepatitis B virus
  25. Re-evaluating the residual risk of transfusion-transmitted Ross River virus infection
  26. Detection of emergent strains of West Nile virus with a blood screening assay
  27. Hepatitis E
  28. The Epidemiology of Imported Malaria and Transfusion Policy in 5 Nonendemic Countries
  29. The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components
  30. First reported case of transfusion‐transmitted Ross River virus infection
  31. Hepatitis E virus: do locally acquired infections in Australia necessitate laboratory testing in acute hepatitis patients with no overseas travel history?
  32. Seroprevalence of Antibodies to Ross River and Barmah Forest Viruses: Possible Implications for Blood Transfusion Safety After Extreme Weather Events
  33. Hepatitis E Virus and Implications for Blood Supply Safety, Australia
  34. Infectivity of blood components from donors with occult hepatitis B infection - results from an Australian lookback programme
  35. A refined method for estimating the size of the potential blood donor pool in Australia
  36. Understanding noncompliance with selective donor deferral criteria for high-risk behaviors in Australian blood donors
  37. Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection
  38. Compliance with the current 12-month deferral for male-to-male sex in Australia
  39. A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening
  40. Implications of Dengue Outbreaks for Blood Supply, Australia
  41. Trends in transfusion-transmissible infections among Australian blood donors from 2005 to 2010
  42. Malaria antibody persistence correlates with duration of exposure
  43. Two cases of asymptomatic HBV “vaccine breakthrough” infection detected in blood donors screened for HBV DNA
  44. Surveillance of Transfusion-Transmissible Infections
  45. Duration of Ross River viraemia in a mouse model - implications for transfusion transmission
  46. Malaria antibody testing of Australian blood donors
  47. No evidence of a significantly increased risk of transfusion-transmitted human immunodeficiency virus infection in Australia subsequent to implementing a 12-month deferral for men who have had sex with men (CME)
  48. Can Blood Tranfusion Transmit Cancer? A Literature Review
  49. Assessing the safety and efficacy of a test-based, targeted donor screening strategy to minimize transfusion transmitted malaria
  50. Two HBV DNA+/HBsAg− blood donors identified by HBV NAT in Shenzhen, China
  51. The risk of dengue transmission by blood during a 2004 outbreak in Cairns, Australia
  52. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood
  53. Comparison of the risk of viral infection between the living and nonliving musculoskeletal tissue donors in Australia
  54. Trends in Prevalence of Viral Infections in Australian Musculoskeletal Tissue Donors and Projections of Incidence and Residual Risk, 1993–2004
  55. Emerging viral threats to the Australian blood supply
  56. Estimating the risk of blood donation associated with HIV risk behaviours
  57. Reply
  58. The Risk of HIV, HBV, HCV and HTLV Infection Among Musculoskeletal Tissue Donors in Australia
  59. Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA
  60. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004
  61. Evidence for undetected malaria infection in non-immune Australian travellers not taking chemoprophylaxis
  62. Erratum
  63. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus
  64. The Current Status and Potential Role of Laboratory Testing to Prevent Transfusion-Transmitted Malaria
  65. International Forum: 1
  66. The efficacy of a malarial antibody enzyme immunoassay for establishing the reinstatement status of blood donors potentially exposed to malaria
  67. Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests
  68. Improved efficiency of national HIV, HCV, and HTLV antibody testing algorithms based on sequential screening immunoassays
  69. Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies
  70. Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies